Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis


*Veterinary Medicine Research and Development, Zoetis Inc., 333 Portage Street, Kalamazoo, MI, 49007, USA
†Veterinary Operations, Zoetis Inc., 5 Giralda Farms, Madison, NJ, 07940, USA
‡Veterinary Medicine Research and Development, Zoetis Inc., Hoge Wei 10, Zaventem, B-1930, Belgium

Correspondence: Sallie B. Cosgrove, Veterinary Medicine Research and Development, Zoetis Inc., 333 Portage Street, Kalamazoo, MI 49007, USA. E-mail: sallie.b.cosgrove@zoetis.com

Background – Oclacitinib (Apoquel™) inhibits the function of a variety of pro-inflammatory, pro-allergic and pruritogenic cytokines that are dependent on Janus kinase enzyme activity. Oclacitinib selectively inhibits Janus kinase 1.

Hypothesis/Objectives – We aimed to evaluate the safety and efficacy of oclacitinib for the control of pruritus associated with allergic dermatitis in a randomized, double-blinded, placebo-controlled trial.

Methods – Client-owned dogs (n = 436) with moderate to severe owner-assessed pruritus and a presumptive diagnosis of allergic dermatitis were enrolled. Dogs were randomized to either oclacitinib at 0.4–0.6 mg/kg orally twice daily or an excipient-matched placebo. An enhanced 10 cm visual analog scale (VAS) was used by the owners to assess the severity of pruritus from day 0 to 7 and by veterinarians to assess the severity of dermatitis on days 0 and 7. Dogs could remain on the study for 28 days.

Results – Pretreatment owner and veterinary VAS scores were similar for the two treatment groups. Oclacitinib produced a rapid onset of efficacy within 24 h. Mean oclacitinib Owner Pruritus VAS scores were significantly better than placebo scores (P < 0.0001) on each assessment day. Pruritus scores decreased from 7.58 to 2.59 cm following oclacitinib treatment. The day 7 mean oclacitinib Veterinarian Dermatitis VAS scores were also significantly better (P < 0.0001) than placebo scores. Diarrhoea and vomiting were reported with similar frequency in both groups.

Conclusions and clinical importance – In this study, oclacitinib provided rapid, effective and safe control of pruritus associated with allergic dermatitis, with owners and veterinarians noting substantial improvements in pruritus and dermatitis VAS scores.

Introduction

Dermatological problems are the second most common reason for dogs to present to veterinary practices.1,2 These frequently include pruritic conditions, such as parasitic infestations and allergic skin diseases.3–5 Veterinarians treating pruritic dogs have the following two goals: (i) to reduce or eliminate the pruritus, which breaks the itch cycle, allowing the skin to heal, preventing chronic inflammatory changes and secondary infection, and reducing patient and owner discomfort and distress; and (ii) to diagnose and manage the cause of the pruritus.6–9

Glucocorticoids are widely used to treat pruritic dogs. They are highly effective, but short-term and chronic adverse effects are common. Acute problems, such as polyuria, polydipsia, polyphagia, inappropriate urination in homes, behavioural changes and panting, can be a problem for the pet owner, interfere with the quality of life of the dog and result in decreased owner compliance. Long-term administration of glucocorticoids may result in serious health conditions, including pancreatitis, gastrointestinal ulceration, lipidaemia, diabetes mellitus, muscle wasting and iatrogenic hyperadrenocorticism.6,9 Topical glucocorticoids can be effective and well tolerated10 but are not suitable for generalized pruritus. Antihistamines have shown only minimal efficacy in the treatment of canine pruritus.11 Systemic ciclosporin and topical tacrolimus can effectively control atopic dermatitis, but the delayed onset of action makes it impractical as a stand-alone therapy for the rapid management of pruritus.11 Essential fatty acids can improve the skin barrier and help to ameliorate atopic dermatitis, but are generally not the first choice treatment to control acute pruritus.12

The pathophysiology of pruritus is complex and, until recently, poorly understood. Recent research has shown that pruritogenic cytokines are a major stimulus of pruritic behaviour in dogs.13 This knowledge has allowed researchers to investigate more targeted and effective...
antipruritic therapies. Oclacitinib is a novel targeted therapy that selectively inhibits key pathways involved in itch and inflammation associated with allergy. Oclacitinib selectively inhibits Janus kinase 1-dependent cytokines in cellular assays with minimal effects against Janus kinase 2-dependent cytokines involved in haematopoiesis. Janus kinase 1 enzyme activities play a central role in cytokine signalling and are involved in the signal transduction of many pro-inflammatory, pro-allergic and prurito-genic cytokines implicated in atopic dermatitis, including interleukin (IL)-2, IL-4, IL-6 and IL-13. Janus kinases are also involved in the signalling of IL-31, a recently identified cytokine that has been shown to play a key role in canine pruritus. Oclacitinib has been shown to inhibit IL-31 cytokine function strongly in dogs and thus it may significantly reduce pruritus.

The aim of this study was to evaluate the safety and efficacy of oclacitinib compared with a placebo for the control of pruritus associated with allergic dermatitis in client-owned dogs.

Materials and methods
Study design
The study was conducted as a double-blinded, placebo-controlled clinical trial with a randomized complete block design replicated at 26 sites throughout the USA; 24 of the participating veterinarians were general practitioners with an interest in dermatology and two were veterinary dermatology specialists.

Oversight
This study complied with all applicable animal welfare regulations related to the humane care and use of animals. The protocol was approved by each study site’s Institutional Animal Care and Use Committee (IACUC) prior to initiation of the study at that site. For those sites in which there was no IACUC, the protocol was reviewed and approved prior to study initiation by the Pfizer Ethical Review Board. The study was conducted in compliance with Guidance for Industry Good Clinical Practice, No. 85 (ICH GLB). The owners gave written informed consent for each dog to participate in the study.

Inclusion criteria
All dogs were client owned, 6 months of age or older and in overall good health based on the initial (day 0) physical examination. Dogs had to weigh between 3 and 80 kg. Dogs were assessed by their owners as having moderate to severe itching (pruritus), using a categorical scale. A presumptive diagnosis of pruritus associated with allergic dermatitis was established based on the dog’s history, clinical signs and the owner’s presenting complaint. Veterinarians attributed the dog’s pruritic condition to one or more of the following presumptive diagnoses: atopic dermatitis (AD), flea allergy dermatitis, food allergy dermatitis, contact dermatitis, sarcoptic mange or an unspecifi ed allergic dermatitis. Dogs in which sarcoptic mange was suspected were skin scraped; however, the presence of a mite was not required for enrolment.

Dogs with other conditions that required concomitant treatment could be enrolled if the treatment remained the same for at least the 6 weeks prior to the study and no change in medication was anticipated during the study. Appropriate flea or sarcoptic mange treatment was implemented where evidence was found on examination or where infestation with fleas or sarcoptic mites was suspected but not definitively confirmed. All dogs were maintained on appropriate flea prevention for the duration of the study. Dogs that were receiving a hypoallergenic diet to manage previously diagnosed adverse food reactions had to have been on that diet for at least 6 weeks prior to day 0 and must have remained on the same diet during the study. Dogs that were presumed to be food allergic on day 0 were permitted to start on a hypoallergenic diet at the time of the day 0 visit. Intra-dermal allergen tests had to have been conducted at least 8 weeks prior to the start of the study. Concomitant allergen-specific immunotherapy had to have been ongoing for at least 6 months prior to enrolment and the protocol must have been maintained throughout the study. If allergen-specific immunotherapy was discontinued, it had to be discontinued at least 8 weeks prior to enrolment.

Prohibited and conditionally allowed medications and therapies
Withdrawal times for prohibited medications were as follows: long-acting injectable glucocorticoids, 6 weeks; oral glucocorticoids, ciclosporin, long-acting injectable antimicrobial agents and miscellaneous compounds with known antipruritic activity (e.g. Staphylococcus lysa te (SPL)C7, Delmont Laboratories Inc., Swarthmore, PA, USA), gabapentin, monoamine oxidase inhibitors and tacrolimus), 4 weeks; topical nonsteroidal anti-inflammatory drugs and topical glucocorticoids, 3 weeks; antibiotics, 2 weeks; and oral antibacterial/antifungal agents, 1 week.

Exclusion criteria
Exclusion criteria included the following: dogs with evidence of malignant neoplasia, demodicosis or immune suppression, such as hyperadrenocorticism; dogs that were receiving or should have been receiving antimicrobial therapy for bacterial folliculitis or fungal dermatitis; and lactating bitches or dogs (male or female) intended for use as breeding animals. Dogs with clinically significant abnormalities in their pretreatment complete blood count, serum chemistry or urinalysis tests were withdrawn from the study.

Randomization and masking
Dogs were randomized to one of two treatment groups (i.e. oclacitinib or placebo) in a 1:1 ratio. Blocking was based on order of enrolment within clinic. The dog was the experimental unit.

All clinical trial personnel, the owner and the laboratory were blinded to the treatment group assignments. The placebo and oclacitinib tablets were identical in size and appearance. An interactive voice response system (IVRS; Almac Clinical Technologies, Yardley, PA, USA) was used to manage patient treatment assignment and blinded drug dispensing. Upon each dog’s enrolment, the sites accessed the IVRS system, and the system then randomized the dogs to the respective treatment group.

Drug administration
Dogs in the oclacitinib treatment group were given oclacitinib maleate caplets orally at a dose of 0.4–0.6 mg/kg twice daily. The scored caplets were provided in three strengths containing 3.6, 5.4 and 16 mg of oclacitinib. Dogs in the placebo treatment group were given the same number of caplets, identical in appearance to oclacitinib maleate caplets and containing all of the same excipients except oclacitinib maleate. Owners administered the study drug at home, with or without food, and were instructed to maintain as close to a 12 h interval between doses as possible.

Study schedule and variables measured
Following randomization, the dogs were assigned to receive either the excipient placebo or oclacitinib at a dose of 0.4–0.6 mg/kg, orally twice daily from day 0 to day 7 (+3 days; study phase). If, in the veterinarian’s clinical judgment, the pruritic condition resolved or improved to a point that no additional therapy was indicated, day 7 was regarded as the final study day. Dogs in which the underlying diagnosis (presenting complaint) was not resolved at the end of the study phase, but that had responded well to therapy, were permitted to remain on therapy (either placebo or oclacitinib) up to day 28 (+2 days; continuation phase). Certain concurrent medications not permitted for use on days 0–7 could be added on or after day 8 (e.g. C226 © 2013 Zoetis Inc. Veterinary Dermatology published by John Wiley & Sons on behalf of the ESVD and the ACVD.
systemic antimicrobial drugs). Glucocorticoids, antihistamines, ciclosporin or other immunosuppressive drugs were not permitted during either phase of the study. Dogs were withdrawn if the owner or veterinarian felt that their pruritus and/or dermatitis required treatment with a prohibited medication. Owners were free to withdraw their dog at any point.

Baseline data (demographics, physical examination, assessments of pruritus and dermatitis, and whether flea control was applied on day 0) were collected on enrolment at day 0. An enhanced visual analog scale (VAS) score was used by both dog owners and veterinarians. The VAS scale consisted of a 10 cm line with word descriptors at 2 cm intervals. Owners were asked to assess the severity of the 'itch', and veterinarians were asked to assess the severity of 'dermatitis' (Figure 1a,b). The enhanced Owner Pruritus VAS had six descriptors of pruritus evenly spaced at 2 cm intervals with ‘normal dog’ at 0 cm and ‘extremely severe itching’ at 10 cm. The enhanced Veterinarian Dermatitis VAS had six descriptors of dermatitis evenly spaced at 2 cm intervals with ‘normal dog’ at 0 cm and ‘extremely severe dermatitis’ at 10 cm.

Owners and veterinarians were instructed to place a mark on the VAS line at the location that best represented the dog’s pruritus or dermatitis, respectively. At study completion, the distance (in centimetres) from the bottom of the line (‘normal dog’) to the owner’s or veterinarian’s mark on the line was measured and recorded. Owners performed a VAS assessment on days 0, 1, 2, 3, 4, 5, 6 and 7. Veterinarians performed a VAS assessment on days 0 and 7 and (when applicable) at all visits occurring during the continuation phase. Assessments were required to be performed by the same owner or veterinarian at all time points.

Blood samples (complete blood count and serum chemistry) were collected on day 0 (prior to dosing), on day 7 and (when applicable) at all visits occurring during the continuation phase. Samples for urinalysis were collected on day 0 (prior to dosing), on day 7 and (when applicable) at all visits occurring during the continuation phase. Samples for urinalysis were sent to a central laboratory (Heska Corporation, Loveland, CO, USA).

To be included in the efficacy analyses, dogs had to have been on study until day 5 and had to have received a minimum of 80% of their intended doses (as recorded in a daily log) on days 0–7. The same individuals (owner and veterinarian) had to perform all assessments for the enrolled dogs. For the analysis of the owner (not veterinarian) assessments, there was an additional requirement that dogs had been properly dosed (two doses in the previous 24 h) and that there were at least five of eight evaluable Owner Pruritus VAS scores between days 0 and 7. Data were analysed using SAS version 9.2 (SAS Institute, Cary, NC, USA). The level of significance was set at \( P < 0.05 \).

Owner Pruritus VAS scores were analysed with a linear mixed model for repeated measures. The model included the fixed effects of baseline, treatment and baseline by treatment interaction, time and the interaction of treatment by time. Random effects included clinic by treatment interaction, between-animal error, clinic by treatment by time interaction and the residual variation. Baselines were centred for inclusion in the model by subtracting the mean baseline value from an individual animal’s value at day 0. Given that the treatment by time interaction was significant \( P < 0.05 \), treatment was compared at each time point.

The effectiveness variables assessed were as follows: (i) Owner Pruritus VAS scores at each assessment day; (ii) Veterinarian Dermatitis VAS scores on day 7; (iii) dogs achieving a 2 cm reduction compared with baseline in Owner Pruritus VAS scores at each assessment day; (iv) dogs achieving a ≥50% reduction compared with baseline in Owner Pruritus VAS scores on day 7; and (v) the proportion of dogs that were treatment successes based on the Owner Pruritus VAS assessment on days 1–7. Treatment success was defined as achieving at least a 2 cm reduction from baseline score on day X on the Owner Pruritus VAS assessment (day 0 score minus day X score ≥ 2 cm) on at least five of the seven study days assessed. If the criteria for treatment success were not met, the

**Efficacy outcome measures**

**Figure 1.** (a) Enhanced Owner Pruritus visual analog scale (VAS). (b) Enhanced Veterinarian Dermatitis VAS.
case was a treatment failure; this included dogs withdrawn prior to
day 7 for an adverse event or for worsening skin condition.

The Veterinarian VAS scores were analysed with a linear mixed
model including the fixed effects of (centred) baseline, treatment and
centered baseline by treatment interaction, and the random effects
of clinic, clinic by treatment interaction and residual variation.

A generalized linear mixed model for repeated measures using a
logit link function and binomial error distribution was used to analyse
the data of 7 cm and a 50% reduction from baseline in Owner Pruritus VAS
scores. The fixed effects were treatment, time and treatment by
time interaction, while the random effects were clinic, clinic by treat-
mament interaction and residual variation. The proportion of success with 95% confi-
dence interval for each treatment and the odds ratio with 95% confidence interval comparing the treatments was reported.

To evaluate the effect of flea or sarcoptic mange treatment on the
effectiveness of oclacitinib for pruritus, the primary variable, treat-
mament success at day 7, was stratified by flea control/sarcoptic mange
control/none and the proportion of treatment success calculated for
each strata.

Safety outcome measures
All enrolled dogs that were administered at least one dose of test arti-
cle were included in the safety analysis. For each continuous haema-
tology and serum chemistry measure, summary statistics (mean, median, SDs, minimum and maximum) were calculated by treatment and time point. Frequencies of dogs reported to experience at least one abnormal health event were displayed by clinical sign for all unique terms. Frequency tables summarizing the number of dogs receiving each medication over the course of the study were prepared.

Results

Demographics
A total of 436 dogs were enrolled (Table 1). Approximately 69% of the dogs were purebred. Retrievers and terriers were the most common dog breed groups, comprising 15.8% (Labrador retrievers 10.3% and golden retrievers 5.5%) and 13.9% of the study population, respectively.

Table 1. Baseline characteristics of enrolled dogs

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo group</th>
<th>Oclacitinib group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breed distribution [n (%)]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed breed</td>
<td>153 (69.5)</td>
<td>148 (68.5)</td>
</tr>
<tr>
<td>Purebred</td>
<td>67 (30.5)</td>
<td>68 (31.5)</td>
</tr>
<tr>
<td>Sex distribution [n (%)]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>114 (51.8)</td>
<td>105 (48.6)</td>
</tr>
<tr>
<td>Male</td>
<td>106 (48.2)</td>
<td>111 (51.4)</td>
</tr>
<tr>
<td>Mean age at study onset [years (range)]</td>
<td>5.8 (1.0–16)</td>
<td>6.0 (0.5–18)</td>
</tr>
<tr>
<td>Mean weight at study onset [kg (range)]</td>
<td>20.0 (3.0–61.7)</td>
<td>20.6 (3.0–56.0)</td>
</tr>
<tr>
<td>Owner Pruritus VAS score at study onset [arithmetic mean; cm]</td>
<td>7.58</td>
<td>7.39</td>
</tr>
<tr>
<td>Veterinarian Dermatitis VAS score at study onset [arithmetic mean; cm]</td>
<td>6.18</td>
<td>6.20</td>
</tr>
</tbody>
</table>
| Presumptive diagnoses for dogs enrolled in the study are shown in Table 2. It was not always possible to stipu-
late a single prescriptive diagnosis, and enrolled dogs could have had more than one prescriptive cause for the
reason for their pruritus associated with allergic dermati-
ts. The presumptive diagnoses were similar in each of the
two treatment groups. Over 80% of the dogs in each
group had a prescriptive diagnosis of atopic dermatitis,
but only 41.5% had atopic dermatitis alone. Slightly more
than 30% of the dogs were presumed to have flea allergy
dermatitis, slightly more than 20% had food allergy der-
matitis, and approximately 10% had contact dermatitis.
Approximately 5% of the dogs had a prescriptive diagno-
sis of sarcoptic mange, although mange mites were not
always observed. A variety of other reasons were noted
for the remaining 5% of the dogs enrolled. All of the
cases with presumptive diagnoses of ‘other’ also had ato-
pic dermatitis, except for one oclacitinib group dog with
the ‘other’ diagnosis of ‘unspecified allergic dermatitis’.

Assessment of effectiveness
The effectiveness data set for the Owner Pruritus VAS
comprised 407 (204 placebo- and 203 oclacitinib-treated)
dogs. The effectiveness data set for the Veterinarian Der-
matitis VAS comprised 413 (207 placebo- and 206 oclaciti-
nib-treated) dogs. Twenty-nine dogs (13 oclacitinib
treated and 16 placebo treated) were excluded from the
Owner Pruritus VAS analyses, and 23 dogs (10 oclacitinib
-treated and 13 placebo treated) were excluded from the
Veterinarian Dermatitis VAS analyses for errors in compli-
ance with the trial and data collection protocols.

Owner Pruritus VAS scores by day of study
The mean day 0 Owner Pruritus VAS scores were very
similar between the treatment groups (7.39 and 7.58 cm
for the oclacitinib-treated dogs (range 4.7–10.0) and pla-
cebo-treated dogs (range 3.0–9.9), respectively; Figure 2)
corresponding to ‘severe itching’ on the enhanced Owner
Pruritus VAS score. After 1 day of treatment, a 2.20 cm
change was observed for the oclacitinib-treated dogs (range 4.7
–9.9), respectively; Figure 2)

Table 2. Presumptive diagnoses at enrolment

<table>
<thead>
<tr>
<th>Presumptive diagnosis</th>
<th>Oclacitinib group [n (%)]</th>
<th>Placebo group [n (%)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic dermatitis</td>
<td>175 (81.0)</td>
<td>179 (81.4)</td>
</tr>
<tr>
<td>Flea allergy dermatitis</td>
<td>72 (33.3)</td>
<td>70 (31.8)</td>
</tr>
<tr>
<td>Food allergy dermatitis</td>
<td>49 (22.2)</td>
<td>51 (23.2)</td>
</tr>
<tr>
<td>Contact dermatitis</td>
<td>24 (11.1)</td>
<td>23 (10.5)</td>
</tr>
<tr>
<td>Sarcoptic mange</td>
<td>2 (0.9)</td>
<td>8 (3.6)</td>
</tr>
<tr>
<td>Other</td>
<td>12 (5.6)</td>
<td>10 (4.5)</td>
</tr>
</tbody>
</table>

Abbreviation: VAS, visual analog scale.
Mean VAS score (cm)

Placebo (n = 203) Oclacitinib (n = 204)

Extremely severe
Severe
Moderate
Mild
Very mild
Normal

Figure 2. Owner Pruritus VAS score by day of study (day 0, arithmetic mean; days 1–7, least squares mean ± 95% confidence interval).

Veterinarian Dermatitis VAS scores decreased for oclacitinib-treated dogs to 2.59 cm (a 4.89 cm reduction in VAS pruritus scores, which corresponds to an approximate reduction from ‘severe itching’ to ‘very mild itching’) and for placebo-treated dogs to 5.54 cm (a 1.94 cm reduction in VAS pruritus scores, which corresponds to an approximate reduction from ‘severe itching’ to ‘moderate itching’). The reduction in the Owner Pruritus VAS scores (2.20 cm) for oclacitinib-treated dogs after 1 day of treatment exceeded the reduction in pruritus scores for placebo-treated dogs after 7 full days of therapy (1.94 cm).

Veterinarian Dermatitis VAS scores decreased for oclacitinib-treated dogs (range 4.0–6.18 cm), which corresponds to an approximate reduction from ‘severe dermatitis’ to ‘moderately severe dermatitis’; Figure 3. The Veterinarian Dermatitis VAS scores were also assessed at the end of the continuation phase (days 8–28) of the study. ~2.5 times more oclacitinib-treated dogs (n = 179) than placebo-treated dogs (n = 73) were treated during that phase. Owing to this imbalance, Veterinarian Dermatitis VAS scores were not compared during the continuation phase.

Dogs achieving a 2 cm Owner Pruritus VAS score reduction each day of the study

On day 1, a 2 cm reduction in Owner Pruritus VAS was observed in 44% of the oclacitinib-treated dogs compared with 19% of the placebo-treated dogs. By day 7, 86.4% of the oclacitinib-treated dogs compared with 42.5% of the placebo-treated dogs achieved a 2 cm reduction in Owner Pruritus VAS scores. The numbers and percentages of dogs achieving a 2 cm reduction in the Owner Pruritus VAS score for each day of the study are shown in Figure 4.

Dogs achieving a ≥50% reduction from baseline in Owner Pruritus VAS and Veterinarian Dermatitis VAS scores on day 7

On day 7, 70.5% of the oclacitinib-treated dogs compared with 23.2% of the placebo-treated dogs achieved a ≥50% reduction in Owner Pruritus VAS scores (P < 0.0001). The numbers and percentages of dogs achieving a ≥50% reduction in the Owner Pruritus VAS score for each day of the study are shown in Figure 5.

Treatment success

Sixty-seven per cent of oclacitinib-treated dogs and 29% of placebo-treated dogs were considered a treatment success; the difference was significant (P < 0.0001). The study also evaluated the effect of flea treatment on treatment success. Flea treatment was initiated on day 0 for 19% (n = 41) and 13% (n = 29) of the dogs in the oclacitinib and placebo treatment groups, respectively. Within...
of treatment. Treatment was stopped in one oclacitinib-treated dog after 7 days because of darkening areas of skin and fur.

The continuation phase (days 8–30) of the study was three times longer than the study phase of the study and contained approximately 2.5 times more oclacitinib maleate (179) than placebo group dogs (73). Six dogs (four oclacitinib and two placebo group) were withdrawn from the study during the continuation phase for abnormal health events. Abnormal health events were reported in 11 of 179 oclacitinib-treated dogs post-study. These were as follows: diarrhoea (four dogs; severe enough to warrant cessation of treatment in one dog); vomiting (four dogs); fever, lethargy and cystitis (one dog); an inflamed footpad and vomiting (one dog); and diarrhoea, vomiting and lethargy (one dog).

**Clinical pathology**

Minor changes were seen in clinical pathology parameters, but these remained within normal laboratory reference ranges. Mean lymphocyte counts for dogs in the oclacitinib group were increased at day 7, but these returned to pretreatment levels within 28 days without a break in oclacitinib administration. These dogs also had a slight decrease in mean white blood cell counts (neutrophil, eosinophil and monocyte counts), but these remained within the normal reference ranges. Serum cholesterol increased in 25% of oclacitinib-treated dogs, but levels remained within the reference range. The incidence of elevated liver enzyme activity for alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase was similar in dogs in the oclacitinib and placebo groups.

**Concomitant medications**

A wide variety of concomitant medications were used in conjunction with either placebo or oclacitinib treatment. The concomitant medications administered most often (in ≥2% of the oclacitinib-treated dogs) are summarized by drug class and treatment group in Table 4. A variety of 

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Oclacitinib group [n = 216; n (%)]</th>
<th>Placebo group [n = 220; n (%)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endectocides</td>
<td>145 (67.1)</td>
<td>150 (68.2)</td>
</tr>
<tr>
<td>Ectoparasiticides, insecticides and repellents</td>
<td>105 (48.6)</td>
<td>101 (49.9)</td>
</tr>
<tr>
<td>Canine vaccines</td>
<td>26 (12.0)</td>
<td>25 (11.4)</td>
</tr>
<tr>
<td>Glucosamine (with and without chondroitin) and nonsteroidal anti-inflammatory products</td>
<td>6 (2.8)</td>
<td>17 (7.7)</td>
</tr>
<tr>
<td>Systemic antibacterials</td>
<td>17 (7.9)</td>
<td>11 (5.0)</td>
</tr>
<tr>
<td>Omega-3 fatty acid preparations</td>
<td>7 (3.2)</td>
<td>7 (3.2)</td>
</tr>
<tr>
<td>Ophthalmologics</td>
<td>13 (6.0)</td>
<td>6 (2.7)</td>
</tr>
<tr>
<td>Oclacitinib</td>
<td>2 (0.9)</td>
<td>5 (2.3)</td>
</tr>
</tbody>
</table>

*Administered to ≥2% of the oclacitinib-treated dogs. 
†Administered in decreasing order of frequency in the oclacitinib treatment group. 
‡Number and percentage are given on a per animal basis. 
§Administered during the continuation phase.
other products were used less frequently (in ≤2% of the oclacitinib-treated dogs) but were administered to a similar number and percentage of dogs in both treatment groups, including thyroid medications, antibacterial products, systemic and topical antifungal products, while skin emollients and skin protectives, as well as vitamins were given to slightly more dogs in the oclacitinib-treated group than in the placebo-treated group.

Discussion

This study provides evidence of the effectiveness of oclacitinib in the control of pruritus associated with allergic dermatitis in dogs. There was a highly significant improvement (P ≤ 0.0001) for all of the efficacy variables in oclacitinib-treated dogs compared with placebo-treated dogs. Following 7 days of oclacitinib treatment, there was a 65% reduction in pruritus scores (from ‘severe itching’ to ‘very mild itching’) and a 64% reduction in clinical severity scores (from ‘moderately severe dermatitis’ to ‘mild dermatitis’). Within the first 24 h of treatment, pruritus scores were reduced by at least 2 cm in 44% of oclacitinib-treated dogs compared with 19% of the placebo-treated dogs. By day 7, 86.4% of the oclacitinib-treated dogs compared with <42.5% of the placebo-treated dogs achieved a 2 cm reduction in Owner Pruritus VAS scores. Additionally, by day 7, 70.5% of oclacitinib-treated dogs showed a ≥50% reduction in Owner Pruritus VAS scores compared with <23.2% of the placebo-treated dogs. Based on the binary treatment success analysis, the majority of oclacitinib-treated dogs (66.5%) were a treatment success compared with only 29.4% of the placebo-treated dogs, with owners and veterinarians noting substantial improvement in pruritus and dermatitis VAS scores. Oclacitinib therefore appears to improve pruritus and dermatitis substantially, affording the damaged skin an opportunity to heal, while allowing the veterinarian time correctly to diagnose and treat the underlying cause. The rapid and effective reduction in pruritus could also greatly improve the quality of life for the affected dogs and their owners.

Immediate downregulation of the action of pruritogenic cytokines, including IL-31, may in part explain the rapid reduction in pruritus following oclacitinib treatment.13 The placebo-treated group also had an immediate but lesser reduction in pruritus score on the first treatment day, which may be attributed in part to a placebo effect but could also be explained by the flea control administered at the start of the study in many of the dogs. The improvement in the clinical severity scores was probably a consequence of controlling the dogs’ pruritus, but may also have reflected a direct anti-inflammatory action in the skin. These findings are consistent with the pharmacological properties of oclacitinib, which is a targeted therapy that inhibits key pathways involved in the pathophysiology of skin inflammation.14

Our study used enhanced VAS scales for the assessment of both pruritus and dermatitis. Enhanced VAS scales with severity descriptors at equally spaced intervals along the line have been shown to be an easy and repeatable method for users to assess the severity of pruritus.20,22 Unique to this study was the use of a Veterinar-ian Dermatitis VAS to assess changes in the severity of the dog’s dermatitis at each clinic visit. In previous studies, veterinarians have used a VAS scale to assess pruritus.23 However, dogs may not reliably demonstrate pruritic behaviour in the veterinary clinic and therefore the veterinarian’s pruritus VAS score may have to rely heavily on what the owner describes rather than what is observed. By comparison, the dermatitis VAS allowed the veterinarian to assess changes in the dog’s skin lesions. More objective and validated assessment tools, such as Canine Atopic Dermatitis and Severity Index (CADESI), are available, but these are limited to specific dermatoses, such as atopic dermatitis, and would have been unsuitable to assess the severity of the variety of skin conditions seen in this study. The enhanced dermatitis VAS was simple and could be used successfully and reliably by general practitioners without special training in dermatology.

For the treatment success analysis, the continuous variable of Owner Pruritus VAS scores collected repeatedly over 7 days was converted to a single binary score for each case, either treatment success or treatment failure. To be classified as a treatment success, the following two criteria had to be met: first, the pruritus score had to improve by a full category (2 cm or more reduction from baseline) on the enhanced Owner Pruritus VAS; and second, the reduction in pruritus (≥2 cm) had to be achieved on ≥6 of the first 7 days of Owner Pruritus VAS assessments. Analysis of treatment success established that the pruritus score improvement was not only statistically different from the placebo group but was of a repeated magnitude (≥2 cm) anticipated to be clinically relevant to both the owner and veterinarian without extrapolating data for cases withdrawn early or interpolating data for missing cases at day 7. The downside to this analysis is that cases with efficacy satisfactory to the owner (e.g. 1.9 cm pruritus reduction or ≥2 cm on four of seven days) were counted as treatment failures. Not surprisingly, the proportion of dogs that were a treatment success (66.5%) was lower than the percentage of dogs that achieved a 2 cm pruritus VAS score reduction from baseline (85%) after 7 days of oclacitinib treatment. Treatment success analysis adds methodological rigour but may underestimate the oclacitinib effectiveness at reducing pruritus observed by the owner and/or veterinarian.

It is difficult to compare the efficacy of oclacitinib directly with that of other antipruritic and anti-inflammatory treatments. Previously reported clinical trials have been conducted in different target populations, predominantly in dogs with atopic dermatitis, without the inclusion of cases with other causes of allergic dermatitis, and have used different measures to assess efficacy (predominantly CADESI).10,24–29 However, the proportion of dogs that achieved a ≥50% reduction in pruritus in this study is comparable to or better than the proportion of atopic dogs that improved to this extent following treatment with topical hydrocortisone aceponate, topical triamcinolone, systemic glucocorticoids and systemic ciclosporin.4,30,31

To the authors’ knowledge, there are no published studies reporting the efficacy of glucocorticoids in dogs.
suffering from allergic dermatitis (i.e. not only atopic dermatitis) or non-specific pruritus despite the fact that this class of drug is the most frequently used for the short-term control of pruritus in dogs. The popularity of glucocorticoids seems to be based on the fast speed of onset and reliable results in any of a number of conditions. This study shows that oclacitinib shares these advantages in dogs with pruritus associated with a number of underlying causes of allergic dermatitis, including atopic dermatitis, flea allergy, food allergy, contact dermatitis and sarcoptic mange. In particular, oclacitinib demonstrated significantly better efficacy than placebo at 24 h, indicating a rapid speed of onset. The rapid onset of response to oclacitinib administration has also been reported in a model of IL-31-induced pruritus and a model of flea allergy dermatitis. In both studies, oclacitinib administration has also been reported in a model of IL-31-induced pruritus and a model of flea allergy dermatitis. 14, 32 In both studies, oclacitinib administered orally as a single dose at 0.4 mg/kg resulted in a significant (\( P < 0.05 \)) reduction in pruritus within 1 h after administration compared with prednisolone administered at doses of 0.25 and 0.5 mg/kg.

Oclacitinib was well tolerated in these dogs. The frequency and type of abnormal health events were similar between the oclacitinib- and placebo-treated dogs. The most common adverse events were gastrointestinal upsets, such as decreased appetite, vomiting and diarrhoea. These were mostly mild and only rarely required cessation of treatment. The acute effects commonly observed with systemic glucocorticoids (e.g. polyuria, polydipsia, panting, polyphagia and changes in serum biochemistry) were seen in <2% of the oclacitinib-treated dogs. The mean values of all of the clinical pathology parameters analysed fell within the normal reference range for both treatment groups. The favourable safety results reported here are supported by the results of a field trial, in which oclacitinib was administered for 4 months to dogs with atopic dermatitis. 33

This study was carried out to good clinical practice standards. 19 Selection bias in breed, age, sex, weight and clinical severity was not apparent. Randomized treatment allocation was made according to a predetermined allocation code. Detection bias by the owners and investigators was unlikely because they were blinded to treatment allocation. Performance bias was possible, because antiparasite treatment and dietary management changes for some dogs on day 0 could have improved their clinical signs. However, the impact of this on the comparison between oclacitinib and placebo is likely to have been low because the type and frequency of concomitant treatments was comparable between the treatment groups. Attrition bias was present; the analysis excluded dogs that were considered to have had a protocol deviation that affected the collection or integrity of their efficacy data. It is possible that this biased towards a favourable response to treatment, although the numbers never exceeded 8% of the treated dogs and were comparable between the treatment groups and analyses. Inclusion and exclusion criteria established before the trial were used to establish a working diagnosis of pruritus associated with allergic dermatitis. Rigorous criteria to establish a firm diagnosis were not employed, because the aim and design of this study were to assess the efficacy of oclacitinib in short-term management of allergic dermatitis. The authors have also reported a study of longer term (112 days) efficacy in the control of a more specific condition, atopic dermatitis. 33

In the conditions of this study, oclacitinib, a selective Janus kinase inhibitor, administered orally at a dose of 0.4–0.6 mg/kg twice daily, was safe and efficacious in controlling the pruritus associated with allergic dermatitis. Oclacitinib provided relief within 24 h that persisted through the treatment period, with >70% of the treated dogs achieving a >50% reduction in pruritus by day 7.

Acknowledgements

We would like to thank the following veterinarians who enrolled dogs in this study and performed the clinical investigations: Brett Berryhill, Glen Burkett, Jay Butan, Randall R. Carpenter, Terry Cleiks, Jeffrey N. Dizik, Sam Geller, Mary Grabow, Robert Jackson, Mark Lelli, Marc Leven, David Lukof, Patrick McSweeney, Kathleen Neuhoff, Karan Oberhansley, Gregory Paplawsky, Andrew Pickering, Jeffrey Pinkston, Dean Rund, Roger Sifferman, Jason St Romain, Kathy Tater, Bradford J. Theodoroff, Philip VanVranken, Philip Waguespack and Melissa Wiest. We would also like to thank the following Zoetis Inc. colleagues for their invaluable assistance: Candace A. Sousa, Marcia J. Adams, Anne E. Daniels and Nancy L. Savicke.

References

12. Scott DW, Miller WH, Griffin CE. Skin immune system and allergic skin diseases. In: Muller and Kirk’s Small Animal Dermatol-
Oclacitinib for pruritus in allergic dermatitis

Résumé

Contexte – L’oclacitinib (Apoquel™) inhibe la fonction d’une variété de cytokines pro-inflammatoires, pro-allergiques et pruritogènes qui dépendent de l’activité de l’enzyme Janus kinase. L’oclacitinib inhibe sélectivement la Janus kinase 1.

Hypothes/Objectifs – Nous voulons évaluer l’efficacité et l’innocuité de l’oclacitinib pour le contrôle du prurit associé à la dermatite allergique dans une étude contrôlée, randomisée, en double-aveugle, contre placebo.

Méthodes – Des chiens (n = 436) présentant un prurit évalué comme sévère par leurs propriétaires et un diagnostic probable de dermatite allergique, ont été enrôlés. Les chiens ont reçu au hasard soit de l’oclacitinib à 0,4–0,6 mg/kg oralement, deux fois par jour soit un placebo. Une échelle visuelle analogue de 10 cm (VAS) a été utilisée par les propriétaires pour évaluer l’intensité du prurit des jours 0 à 7 et par les vétérinaires pour évaluer la sévérité de la dermatite aux jours 0 et 7. Les chiens pouvaient rester dans l’étude pendant 28 jours.

Résultats – Les scores de VAS de prurit associé à la dermatite allergique, avec les propriétaires et les vétérinaires notant des améliorations conséquentes dans les scores VAS de prurit et de dermatite.

Conclusion et importance clinique – Dans cette étude, l’oclacitinib a permis un contrôle rapide, efficace et sûr du prurit associé à une dermatite allergique, avec les propriétaires et les vétérinaires notant des améliorations conséquentes dans les scores VAS de prurit et de dermatite.

Resumen

Introducción – Oclacitinib (Apoquel™) inhibe la función de una variedad de citocinas proinflamatorias, proalergénicas y pruritogénicas que dependen de la actividad de la enzima Janus quinasa 1.
Hipótesis/Objetivos – nuestro propósito fue evaluar la seguridad y eficacia de oclacinib para el control del prurito asociado con dermatitis alérgica en un estudio al azar, doble ciego y controlado con placebo.

Métodos – perros de propietarios particulares (n = 436) con prurito de moderado a severo en opinión de los propietarios y con un diagnóstico presuntivo de dermatitis alérgica se incluyeron en el estudio. Los perros fueron distribuidos al azar para recibir oclacinib a dosis de 0,4-0,6 mg/kg dos veces al día o un placebo compuesto del mismo excipiente. Se utilizó una escala visual análoga aumentada de 10 cm (VAS) para que los propietarios evaluaran la severidad del prurito desde el día 0 al 7 y por los veterinarios para evaluar la severidad de la dermatitis en los días 0 y 7. Los perros podían permanecer en el estudio hasta 28 días.

Resultados – los valores de VAS pretratamiento de los propietarios y veterinarios fueron similares en los dos grupos de tratamiento. Oclacinib produjo un efecto eficaz y rápido a las 24 h. Los valores medios de VAS obtenidos por los propietarios en perros tratados con oclacinib fueron significativamente mejores que los valores de placebo (P < 0,0001) en cada uno de los días evaluado. Los valores de prurito decrecieron de 7,58 a 2,59 cm tras el tratamiento con oclacinib. La media de los valores de VAS en el día 7 obtenidos por los veterinarios también fue significativamente mejor (P < 0,0001) que los valores de animales con placebo. Vómitos y diarrea fueron descritos con igual frecuencia en ambos grupos.

Conclusiones e importancia clínica – en este estudio oclacinib causó un control rápido, efectivo y seguro del prurito asociado con la dermatitis alérgica, y tanto propietarios como veterinarios notaron una mejora sustancial del prurito y de los valores VAS de dermatitis.

Zusammenfassung


Methoden – Hunde im Privatbesitz (n=436) mit moderatem bis starkem von den BesitzerInnen beurteiltem Juckreiz und der Verdachtsdiagnose einer allergischen Dermatitis wurden in die Studie aufgenommen. Die Hunde wurden zufällig aufgeteilt und entweder mit Oclacinib bei einer Dosierung von 0,4-0,6mg/kg per os zweimal täglich oder mit dem Trägermedium angepasstem Plazebo behandelt. Eine verstärkte 10cm visuelle Analogskala (VAS) wurde von den BesitzerInnen verwendet, um den Schweregrad des Juckreizes von Tag 0 bis 7 zu beurteilen und von TierärztInnen wurde sie verwendet, um den Schweregrad der Dermatitis an den Tagen 0 und 7 zu beurteilen. Die Hunde konnten 28 Tage lang an der Studie teilnehmen.


Schlußfolgerungen und klinische Bedeutung – In dieser Studie bewirkte Oclacinib eine rasche, wirksame und sichere Kontrolle der Pruritus, der im Zusammenhang mit einer allergischen Dermatitis auftrat, wobei sowohl BesitzerInnen als auch TierärztInnen bedeutende Verbesserungen des Juckreizes sowie der Dermatitis VAS Werte bemerkten.

要約
背景 – オクラシチニブ(Apoquel™)はレーススターキナーゼ活性による炎症誘導性、アレルギー誘導性、そう も誘導性サイトカインなどの様々な機能を抑制する。オクラシチニブはレーススターキナーゼ1を選択的に抑制する。
仮説/目的 – 症状のない接触性皮膚炎を有する皮膚炎のコントロールのためのオクラシチニブの安全 性および効果をラウンド化、二重盲検、プラセボ対照試験で評価することを目的とした。
方法 – 中等度から重度の痒みと飲食性が評価し、アレルギー性皮膚炎と推定診断した犬(436)が組み入れられた。オクラシチニブの用量は0.4-0.6mg/kg/day 2回、経口投与あるいは消化管スライドをランダムに割り当てられた。変化を10cmビジュアルアナログスケール（VAS）を0日から7日までオクラシチニブによって進行の程度を評価するのに使用し、0日と7日に関節医師によって皮膚炎の重症度を評価するために使用した。328日間試験を続けた。
結果 – 処置前の飲食のないおよび医師のVASスコアは2つの治療群で類似していた。オクラシチニブは24時間以内に急速な効果の発現を示した。平均オクラシチニブ飲食のない羣VASスコアはそれぞれの評価の日でプラセボスコア（P < 0.0001）と比較し有意に改善していた。治療群VASスコアはオクラシチニブの治療によって7.58から2.59に減少した。7日目の平均オクラシチニブ医師皮膚炎VASスコアとプラセボスコアを比較し有意に改善を示し (P < 0.0001)、両群で類似した傾向の下顎および嘔吐が報告された。
結論および臨床的および安全性 – この研究では、飲食のないおよび医師による痒みと皮膚炎VASスコアにおいて顕 著な改善があることから、オクラシチニブが急速で効果的、および安全にアレルギー性皮膚炎に関連した痒みをコントロールできることができた。
摘要

背景 - Oclacitinib (Apoquel®) 对各种促炎、促过敏和引起瘙痒的细胞因子的抑制取决于酪氨酸蛋白激酶的
酶活性。Oclacitinib选择性抑制酪氨酸蛋白激酶1。

假设/目的 - 我们的目的是通过随机、双盲、安慰剂对照试验，评估occlacitinib控制过敏性皮炎的瘙痒的
安全性和功效。

方法 - 主人评估出有中度至严重的瘙痒，并推测诊断为过敏性皮炎的家养犬（n = 436），进行登记。随机
分为两组，给予occlacitinib，0.4 - 0.6 mg/kg/日，每2天一个周期，或给予相匹配的肢形剂为安慰剂。主人使用
改良的10cm视觉类比标准（VAS）评估0-7天瘙痒的严重程度，兽医评估0-7天皮炎的严重程度，持续研究这些
犬28日。

结果 - 处理前两个治疗组中主人和兽医VAS评分相似。Oclacitinib在24小时内快速产生功效。每个评估日
occlacitinib组主人的VAS瘙痒评分，平均值显著优于安慰剂组评分（P < 0.0001）。occlacitinib组兽医的皮炎VAS评分第7日平均值也显著优于（P < 0.0001）安慰
剂组评分。两组中出现呕吐和腹泻的频率相似。

结论和临床价值 - 本研究中，occlacitinib能迅速、有效并安全的控制与过敏性皮炎有关的瘙痒，主人和兽
医的瘙痒和皮炎VAS评分，均可见实质性改善。